Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cerus's Business Segments
Cerus's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Product Other
Total Revenue
$ 57
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product Other2.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product Other | $ 1 | 2.1% |
Revenue by Product & Service Category - FY
- Product0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 54 | - |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product Other2.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product Other | $ 1 | 2.1% |
Description of Cerus
Cerus Corporation is a biopharmaceutical company that has been dedicated to providing solutions for the enhancement of blood safety throughout the world since 1991. Their headquarters are located in Concord, California, and the company has additional facilities in France, Germany, and Switzerland.
Cerus Corporation focuses on the development of innovative technologies that can help prevent the transmission of diseases through blood transfusions. Their primary product is the INTERCEPT Blood System, which provides a broad-spectrum solution for the reduction of pathogens present in donated blood. It is a unique and proprietary technology that works by incorporating an FDA-approved chemical compound, known as amotosalen, to inactivate viruses, bacteria, and parasites in blood products.
The INTERCEPT Blood System targets the transfusion needs of individual patients by customizing blood components to meet their specific needs. This technology can also reduce the risk of transfusion-transmitted infections, such as dengue, Zika, chikungunya, and malaria. As such, it is becoming increasingly adopted in countries around the world, especially those with a high risk of disease transmission through transfusions.
Cerus Corporation's products and technologies have been approved by several regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company collaborates with several Worldwide Health Organisations, blood centers, and hospitals around the world. The INTERCEPT Blood System is used by over 150 centers in 30 countries, with over 5 million INTERCEPT-treated platelet and plasma units in circulation.
The company's management team comprises experts with vast experience in the health sector, which includes the commercialization of innovative blood products, and the successful registration of new pharmaceutical and medical device products globally.
Cerus Corporation is committed to continuously providing innovative products and services to meet necessary patient needs. With a commitment to excellence in research, development, and regulatory clinical trial programs, Cerus Corporation is at the forefront of reducing the risk of blood-borne diseases and ensuring patient safety in transfusion therapies.
Cerus Corporation focuses on the development of innovative technologies that can help prevent the transmission of diseases through blood transfusions. Their primary product is the INTERCEPT Blood System, which provides a broad-spectrum solution for the reduction of pathogens present in donated blood. It is a unique and proprietary technology that works by incorporating an FDA-approved chemical compound, known as amotosalen, to inactivate viruses, bacteria, and parasites in blood products.
The INTERCEPT Blood System targets the transfusion needs of individual patients by customizing blood components to meet their specific needs. This technology can also reduce the risk of transfusion-transmitted infections, such as dengue, Zika, chikungunya, and malaria. As such, it is becoming increasingly adopted in countries around the world, especially those with a high risk of disease transmission through transfusions.
Cerus Corporation's products and technologies have been approved by several regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company collaborates with several Worldwide Health Organisations, blood centers, and hospitals around the world. The INTERCEPT Blood System is used by over 150 centers in 30 countries, with over 5 million INTERCEPT-treated platelet and plasma units in circulation.
The company's management team comprises experts with vast experience in the health sector, which includes the commercialization of innovative blood products, and the successful registration of new pharmaceutical and medical device products globally.
Cerus Corporation is committed to continuously providing innovative products and services to meet necessary patient needs. With a commitment to excellence in research, development, and regulatory clinical trial programs, Cerus Corporation is at the forefront of reducing the risk of blood-borne diseases and ensuring patient safety in transfusion therapies.
Cerus Corporation is a biotechnology enterprise dedicated to enhancing blood safety through innovative solutions that significantly reduce the risk of transfusion-transmitted infections for patients needing blood transfusions. Their focus is on developing advanced medical devices, products, and services aimed at ensuring the safety, efficacy, and quality of blood transfusions.
Segments
1. INTERCEPT Blood System:
The cornerstone of Ceruss offerings, the INTERCEPT Blood System serves as a comprehensive solution for pathogen inactivation in blood components. It is engineered to target and inactivate a broad spectrum of pathogens including viruses, bacteria, and parasites, as well as leukocytes. This system is pivotal in the manufacturing processes of plasma, platelets, and red blood cell components, effectively mitigating the potential risks associated with transfusion-transmitted infections.
2. INTERCEPT Platelet System:
The INTERCEPT Platelet System is another significant segment, focusing specifically on platelet transfusions. This proprietary medical device leverages a photochemical method to inactivate pathogens, thereby safeguarding patients from infections that can arise from transfused platelets.
Products
1. INTERCEPT Blood System for Plasma:
This component of the INTERCEPT Blood System is designed specifically for the inactivation of pathogens during the processing of plasma in blood centers and hospitals. By targeting various viruses and other infectious agents, the system enhances the safety of plasma products for transfusion.
2. INTERCEPT Blood System for Platelets:
Intended for use in blood centers and hospitals, this system works to inactivate pathogens present in platelets. By addressing the risk of transfusion-transmitted infections, it is a critical tool in safeguarding vulnerable patient populations who require platelet transfusions.
3. INTERCEPT Blood System for Red Blood Cells:
This product is optimized for the manufacturing and processing of red blood cell components. It plays an essential role in inactivating a variety of pathogens and leukocytes, thereby reinforcing the safety of red blood cell transfusions and minimizing the potential for infections.
4. INTERCEPT Platelet System:
Specifically tailored for platelet components, this system utilizes a unique photochemical process to inactivate pathogens. It serves to significantly reduce the risk of transfusion-transmitted infections associated with platelet therapies.
Services
1. INTERCEPT Blood System Services:
Cerus Corporation accompanies its product offerings with a suite of support services that include installation, validation, and training for hospitals and blood banks. These services ensure that the INTERCEPT Blood System is effectively integrated and utilized within healthcare settings. Additionally, the company commits to providing ongoing maintenance and support services, enabling facilities to operate the system efficiently over time.
2. INTERCEPT Platelet Services:
Similar to the Blood System Services, these services include the installation and validation of the INTERCEPT Platelet System. Cerus Corporation also extends ongoing support to blood centers and hospitals, ensuring that the functionality and reliability of the platelet systems are maintained throughout their operational life.
Conclusion
In summary, Cerus Corporation stands at the forefront of biotechnology with its innovative blood safety solutions aimed at protecting patients undergoing blood transfusion procedures. Through its main segments—the INTERCEPT Blood System and INTERCEPT Platelet System—the company offers a comprehensive array of products for plasma, platelets, and red blood cells, all designed to decrease the risk of transfusion-transmitted infections. Additionally, Cerus provides essential services to aid in the proper implementation and maintenance of these critical systems, reinforcing its commitment to patient safety and healthcare excellence.
Segments
1. INTERCEPT Blood System:
The cornerstone of Ceruss offerings, the INTERCEPT Blood System serves as a comprehensive solution for pathogen inactivation in blood components. It is engineered to target and inactivate a broad spectrum of pathogens including viruses, bacteria, and parasites, as well as leukocytes. This system is pivotal in the manufacturing processes of plasma, platelets, and red blood cell components, effectively mitigating the potential risks associated with transfusion-transmitted infections.
2. INTERCEPT Platelet System:
The INTERCEPT Platelet System is another significant segment, focusing specifically on platelet transfusions. This proprietary medical device leverages a photochemical method to inactivate pathogens, thereby safeguarding patients from infections that can arise from transfused platelets.
Products
1. INTERCEPT Blood System for Plasma:
This component of the INTERCEPT Blood System is designed specifically for the inactivation of pathogens during the processing of plasma in blood centers and hospitals. By targeting various viruses and other infectious agents, the system enhances the safety of plasma products for transfusion.
2. INTERCEPT Blood System for Platelets:
Intended for use in blood centers and hospitals, this system works to inactivate pathogens present in platelets. By addressing the risk of transfusion-transmitted infections, it is a critical tool in safeguarding vulnerable patient populations who require platelet transfusions.
3. INTERCEPT Blood System for Red Blood Cells:
This product is optimized for the manufacturing and processing of red blood cell components. It plays an essential role in inactivating a variety of pathogens and leukocytes, thereby reinforcing the safety of red blood cell transfusions and minimizing the potential for infections.
4. INTERCEPT Platelet System:
Specifically tailored for platelet components, this system utilizes a unique photochemical process to inactivate pathogens. It serves to significantly reduce the risk of transfusion-transmitted infections associated with platelet therapies.
Services
1. INTERCEPT Blood System Services:
Cerus Corporation accompanies its product offerings with a suite of support services that include installation, validation, and training for hospitals and blood banks. These services ensure that the INTERCEPT Blood System is effectively integrated and utilized within healthcare settings. Additionally, the company commits to providing ongoing maintenance and support services, enabling facilities to operate the system efficiently over time.
2. INTERCEPT Platelet Services:
Similar to the Blood System Services, these services include the installation and validation of the INTERCEPT Platelet System. Cerus Corporation also extends ongoing support to blood centers and hospitals, ensuring that the functionality and reliability of the platelet systems are maintained throughout their operational life.
Conclusion
In summary, Cerus Corporation stands at the forefront of biotechnology with its innovative blood safety solutions aimed at protecting patients undergoing blood transfusion procedures. Through its main segments—the INTERCEPT Blood System and INTERCEPT Platelet System—the company offers a comprehensive array of products for plasma, platelets, and red blood cells, all designed to decrease the risk of transfusion-transmitted infections. Additionally, Cerus provides essential services to aid in the proper implementation and maintenance of these critical systems, reinforcing its commitment to patient safety and healthcare excellence.